## Namita Shanbhag

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11928648/publications.pdf

Version: 2024-02-01

	933447	1125743
463	10	13
citations	h-index	g-index
2.5		601
15	15	691
docs citations	times ranked	citing authors
	citations 15	463 10 citations h-index  15 15

#	Article	IF	CITATIONS
1	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nature Medicine, 2021, 27, 141-151.	30.7	134
2	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut, 2020, 69, 18-31.	12.1	94
3	YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut, 2021, 70, 55-66.	12.1	53
4	Targeting Angiogenesis in Colorectal Carcinoma. Drugs, 2019, 79, 63-74.	10.9	42
5	Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut, 2021, 70, 2238-2248.	12.1	30
6	Recent advances in the management of gastric adenocarcinoma patients. F1000Research, 2018, 7, 1365.	1.6	26
7	Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut, 2021, 70, 2055-2065.	12.1	24
8	Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer, 2020, 23, 904-912.	5.3	15
9	Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Annals of Surgery, 2020, 272, 311-318.	4.2	14
10	Palliative care for advanced gastric cancer. Expert Review of Anticancer Therapy, 2020, 20, 575-580.	2.4	14
11	Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Annals of Surgery, 2021, 273, 751-757.	4.2	8
12	Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology, 2019, 96, 252-258.	1.9	4
13	Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells. Surgery Today, 2020, 50, 1223-1231.	1.5	4